Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech binary events -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (48)	6/5/2003 9:16:18 AM
From: Biomaven	Read Replies (1) \| Respond to of 295

However, they did not say anything about group (inside risk factors) who were progressive after immunotherapy, have measurable metastatic disease and short life expectation. Granted, but it was all I could find. I was able to access the actual paper, and the Kaplan-Meier survival curves look like hyperbolas, with the median survival coming on the early steep part of the curve before it flattens out dramatically. Thus on one of the subgroups with poorest prognosis, with median survival of only 8 months, there was still 20% survival at 2 years. So even though this data is not an exact analogy by any means, it does indicate that there is a substantial survival tail, which means that we could easily see some placebo patients surviving 2+ years. I have less concern than you about the trial itself. These are patients that have been through a brutal regime (IL-2) and failed. At that point it is a reasonable decision to go with a trial offering only palliative care or a drug with no side effects rather than reach for a slim chance with another tough drug. I do have the worry that some of the placebo patients might have decided to take some shark cartilage on their own. If this happened, and it really works, that might yet kill the trial. Peter